VBI

Dec 01 2013

6

VBI’s eVLP-based CMV Vaccine Published in Clinical and Vaccine Immunology

By VBI | Cytomegalovirus ("CMV")

A new paper entitled ‘Enveloped Virus-Like Particle Expression of Human Cytomegalovirus Glycoprotein B Antigen Induces Antibodies with Potent and Broad Neutralizing Activity’ was published this week in Clinical and Vaccine…

VBI Vaccines, has raised $250,000 in funding, according to federal documents. The latest round raises the total amount of funding VBI has received since inception to more than $14 million. Before raising the $250,000, Variation Bio secured $750,000 in June 2013.

http://www.bizjournals.com/boston/blog/bioflash/2013/09/variation-bio-garners-250k-new-funding.html

Feb 13 2012

2

VBI Vaccines has raised $2.2 million in debt financing, federal documents show.

http://www.bizjournals.com/boston/blog/mass-high-tech/2012/02/vbi-vaccines-pulls-in-22m-debt-round.html

Sep 15 2011

3

VBI Vaccines Announces Acquisition of Epixis and Its Innovative eVLP Vaccine Platform

By VBI | Archived Press Releases

VBI Vaccines ("VBI"), a biotechnology company dedicated to the innovative formulation, development and delivery of safe and effective vaccines, announced today that it has completed the acquisition of Epixis S.A., a French biotechnology company developing its “eVLP” platform technology for...

VBI Vaccines has completed the acquisition of Epixis, a French company developing virus-like particle (VLP) vaccines on its eVLP platform. The acquisition is complementary to VBI’s suite of thermostable vaccine formulation technologies and enables VBI to develop its own VLP-based vaccines.

http://genengnews.com/gen-news-highlights/vbi-acquires-epixis-for-vlp-vaccines-capabilities/81245686/

Sep 15 2011

1

VBI Vaccines has completed its acquisition of France's Epixis for an undisclosed sum, giving the company rights to Epixis' platform technology for a new generation of virus-like particle (VLP) vaccines.

http://www.fiercevaccines.com/story/vbi-buys-epixis-gains-cmv-hep-c-vaccines/2011-09-15

Jul 19 2011

0

Cambridge-based vaccine developer Variation Biotechnologies Inc. has raised a combined $7.8 million in a pair of debt financings, according to federal documents filed yesterday.

http://www.bizjournals.com/boston/blog/mass-high-tech/2011/07/variation-biotech-taps-backers-for-78m.html

Mar 24 2011

0

Expect to hear more about the vaccine developer VBI this year. The company has made some progress in addressing a major bugaboo in the vaccine field—the need to keep the vast majority of them at cool or freezing temperatures or risk spoilage.

http://www.xconomy.com/boston/2011/03/24/vbi-progressing-with-vaccines-that-dont-require-refrigeration/

Jan 04 2007

1

Variation Biotechnologies Secures $35.7M in Series A Financing to Fund Innovative Vaccine Platform

By VBI | Archived Press Releases

Variation Biotechnologies Inc. (VBI), a privately held biopharmaceutical company focused on the development of vaccines for infectious diseases using a novel platform technology, announced today it has secured US$35.7 million…

VBI’s eVLP-based CMV Vaccine Published in Clinical and Vaccine Immunology

VBI Vaccines, has raised $250,000 in funding, according to federal documents. The latest round raises the total amount of funding VBI has received since inception to more than $14 million. Before raising the $250,000, Variation Bio secured $750,000 in June 2013.

VBI Vaccines has raised $2.2 million in debt financing, federal documents show.

VBI Vaccines Announces Acquisition of Epixis and Its Innovative eVLP Vaccine Platform

VBI Vaccines has completed the acquisition of Epixis, a French company developing virus-like particle (VLP) vaccines on its eVLP platform. The acquisition is complementary to VBI’s suite of thermostable vaccine formulation technologies and enables VBI to develop its own VLP-based vaccines.

VBI Vaccines has completed its acquisition of France's Epixis for an undisclosed sum, giving the company rights to Epixis' platform technology for a new generation of virus-like particle (VLP) vaccines.

Cambridge-based vaccine developer Variation Biotechnologies Inc. has raised a combined $7.8 million in a pair of debt financings, according to federal documents filed yesterday.

Expect to hear more about the vaccine developer VBI this year. The company has made some progress in addressing a major bugaboo in the vaccine field—the need to keep the vast majority of them at cool or freezing temperatures or risk spoilage.

Variation Biotechnologies Secures $35.7M in Series A Financing to Fund Innovative Vaccine Platform

About VBI Vaccines

Recent News

VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting

VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

VBI Vaccines Announces Third Quarter 2019 Financial Results and Provides Corporate Update